Tipelukast Drug Asset Due Diligence Report 2026

This Tipelukast Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Tipelukast can convert its Small molecule drug profile and 5-LOX x LTRs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tipelukast (query alias: Tipelukast)
Modality / target	Small molecule drug; 5-LOX x LTRs; 5-LOX inhibitors, LTRs antagonists
Highest global status	Phase 2
Originator	KYORIN Pharmaceutical Co., Ltd.
Active developers	KYORIN Pharmaceutical Co., Ltd., MediciNova, Inc.

The MCP disease footprint includes Diabetes Mellitus, Type 2, Metabolic dysfunction-associated steatotic liver disease, Hypertriglyceridemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05464784	Phase 2	Active, not recruiting	40	Primary endpoint not disclosed in English source
NCT02681055	Phase 2	Completed	19	Primary endpoint not disclosed in English source
NCT02503657	Phase 2	Completed	15	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2; n=15; evaluation: Not stated in English source. Reported fields: Absolute Change From Baseline in Forced Vital Capacity for 26 Weeks(Mean) = -0.177 L ; Absolute Change From Baseline in Forced Vital Capacity for 26 Weeks(Mean) = -0.025 L

An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia

Phase 2; n=19; evaluation: Not stated in English source. Reported fields: Mean Change From Baseline at 12 Weeks of MN-001 Treatment on Cholesterol Efflux Capacity(Mean) = -0.013 percentage of cholesterol

MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

Phase 2; n=19; evaluation: Positive. Reported fields: Triglycerides(8-week) = -50.8 % ; Triglycerides(8-week) = -17.8 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tipelukast addresses Diabetes Mellitus, Type 2, Metabolic dysfunction-associated steatotic liver disease, Hypertriglyceridemia. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-06-22	MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan	Phase 2	Financial terms not disclosed
2002-03-14	MediciNova, Inc. licensed MN-166 (ibudilast) from Kyorin Pharmaceuticals (Kyorin) in 2004	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods to decrease triglyceride synthesis in the liver”. The milestone feed surfaced a patent-application signal described as “Quinoline derivative or pharmaceutically acceptable salt thereof for combined treatment of interstitial lung disease”. The milestone feed surfaced a patent-application signal described as “Fatty acid derivatives for treating non-alcoholic steatohepatitis”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO